KARADAĞ, Ö. Et Al. 2024. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: Real life experience from the TReasure Registry. Clinical and Experimental Rheumatology , vol.42, no.1 , 130-137.

KARADAĞ, Ö., Farisogullari, B., YAĞIZ, B., Erden, A., Ademoglu, Z., Kimyon, G., ... YAŞAR BİLGE, N. Ş.(2024). Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: Real life experience from the TReasure Registry. Clinical and Experimental Rheumatology , vol.42, no.1, 130-137.

KARADAĞ, ÖMER Et Al. "Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: Real life experience from the TReasure Registry," Clinical and Experimental Rheumatology , vol.42, no.1, 130-137, 2024

KARADAĞ, ÖMER Et Al. "Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: Real life experience from the TReasure Registry." Clinical and Experimental Rheumatology , vol.42, no.1, pp.130-137, 2024

KARADAĞ, Ö. Et Al. (2024) . "Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: Real life experience from the TReasure Registry." Clinical and Experimental Rheumatology , vol.42, no.1, pp.130-137.

@article{article, author={ÖMER KARADAĞ Et Al. }, title={Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: Real life experience from the TReasure Registry}, journal={Clinical and Experimental Rheumatology}, year=2024, pages={130-137} }